<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196219</url>
  </required_header>
  <id_info>
    <org_study_id>C3J17-206-00</org_study_id>
    <nct_id>NCT03196219</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects</brief_title>
  <acronym>C3J17-206-00</acronym>
  <official_title>A Phase 2, Open-label and Single-Blind Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip Administered in Multiple Doses to Adolescent and Adult Dental Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Armata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label and single-blind phase 2 study to evaluate the oral microbiology, safety and&#xD;
      tolerability of multiple C16G2 Varnish and Strip applications in male and female dental&#xD;
      subjects 12-75 years of age. The study will compare multiple study drug administrations of&#xD;
      C16G2 Varnish and/or C16G2 Strip in three study arms.&#xD;
&#xD;
      In Study Arm 1 eight subjects will be enrolled in an open-label manner and will receive a&#xD;
      daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip&#xD;
      administered over 7 days. Following the three C16G2 Varnish applications, each subject will&#xD;
      receive 7 days of AM and PM dosing with C16G2 Strip and will be followed for microbiology for&#xD;
      up to 2 months after the last study drug administration.&#xD;
&#xD;
      Study Arm 2 will enroll 12 subjects in a single-blind manner. Subjects will receive four&#xD;
      C16G2 Varnish or Placebo applications over 7 days, followed by 3 additional weekly varnish&#xD;
      administrations. Subjects will be followed for microbiology for up to 2 months after the last&#xD;
      study drug administration.The treatment allocation will be 1:1 (6 subjects receiving C16G2&#xD;
      Varnish, 6 subjects receiving Placebo).&#xD;
&#xD;
      Study Arm 3 will be initiated based on the Sponsor's review of all microbiology data up to&#xD;
      two week post last study drug administration from Study Arm 2. If initiated, Study Arm 3 will&#xD;
      enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2&#xD;
      Varnish over 10 days, for a total of 10 doses and will be followed for microbiology for up to&#xD;
      2 months after the last study drug administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label and single-blind phase 2 study to evaluate the oral microbiology, safety and&#xD;
      tolerability of multiple C16G2 Varnish and Strip applications in male and female dental&#xD;
      subjects 12-75 years of age.&#xD;
&#xD;
      The study will compare multiple study drug administrations of 13.6 milligrams (mg) of C16G2&#xD;
      Varnish and 9.2 mg of C16G2 Strip in three study arms. Before dosing of study drug, eligible&#xD;
      subjects will receive professional dental prophylaxis between Days -7 and -2.&#xD;
&#xD;
      In Study Arm 1 eight subjects will be enrolled in an open-label manner and will receive a&#xD;
      daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip&#xD;
      administered over 7 days. C16G2 Varnish will be applied with a small brush typically used in&#xD;
      dental varnish administration. Following the three C16G2 Varnish applications, each subject&#xD;
      will receive 7 days of AM and PM dosing with C16G2 Strip. To evaluate the durability of S.&#xD;
      mutans suppression, study subjects will be followed for microbiology for up to 2 months after&#xD;
      the last study drug administration.&#xD;
&#xD;
      Study Arm 2 will enroll 12 subjects in a single-blind manner. Subjects will receive four&#xD;
      C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 &amp; 7), followed by 3&#xD;
      additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects&#xD;
      receiving C16G2 Varnish, 6 subjects receiving Placebo). To evaluate the durability of S.&#xD;
      mutans suppression, study subjects will be followed for microbiology for up to 2 months after&#xD;
      the last study drug administration.&#xD;
&#xD;
      Study Arm 3 will be initiated based on the Sponsor's review of all microbiology data up to&#xD;
      two week post last study drug administration from Study Arm 2.&#xD;
&#xD;
      If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will&#xD;
      receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses. To&#xD;
      evaluate the durability of S. mutans suppression, study subjects will be followed for&#xD;
      microbiology for up to 2 months after the last study drug administration.&#xD;
&#xD;
      Clinic visits in Study Arm 1 include Visit 1 (Screening/Days -30 to -1), Visit 2&#xD;
      (Prophylaxis/Day -7 to -2), Eligibility Confirmation, Baseline &amp; First C16G2 Varnish Dosing&#xD;
      at Visit 3, Visits 4 &amp; 5 (C16G2 Varnish Administration), Visits 6-19 (AM &amp; PM C16G2 Strip&#xD;
      Administration), Follow-up Visits 20 &amp; 21 (Safety and Microbiology) and Follow-up Visits&#xD;
      22-24 (Microbiology only).&#xD;
&#xD;
      Clinic visits in Study Arm 2 include Visit 1 (Screening/Days -30 to -1), Visit 2&#xD;
      (Prophylaxis/Day -7 to -2), Eligibility Confirmation, Baseline &amp; First C16G2 Varnish or&#xD;
      Placebo Dosing at Visit 3, Visits 4-9 (C16G2 Varnish or Placebo Administration), Follow-up&#xD;
      Visits 10 &amp; 11 (Safety and Microbiology) and Follow-up Visits 12-14 (Microbiology only).&#xD;
&#xD;
      Clinic visits in Study Arm 3 include Clinic Visit 1 (Screening/Days -30 to -1), Visit 2&#xD;
      (Prophylaxis/Day -7 to -2), Eligibility Confirmation, Baseline &amp; First C16G2 Varnish Dosing&#xD;
      at Visit 3, Visits 4-12 (C16G2 Varnish Administration), Follow-up Visits 13 &amp; 14 (Safety and&#xD;
      Microbiology) and Follow-up Visits 15-17 (Microbiology only).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Study Arms 1 and 2 will be enrolled in parallel followed by Study Arm 3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>In the single-blind Study Arm 2, active and placebo will be identical in appearance and labeled in a blinded fashion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial Activity of C16G2</measure>
    <time_frame>Evaluated over up to 2 months</time_frame>
    <description>To assess the targeted antimicrobial activity of C16G2 applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Oral Bacterial Levels</measure>
    <time_frame>1 day post last study drug administration</time_frame>
    <description>Total bacterial levels will be evaluated by measuring colony forming unit (CFU)/mL counts of salivary and plaque bacteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of C16G2 Administrations assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events</measure>
    <time_frame>Up to 7 days post last study drug administration</time_frame>
    <description>Safety will be assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 &amp; 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C16G2</intervention_name>
    <description>C16G2</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Antimicrobial Peptide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Varnish Placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, 12-75 years of age&#xD;
&#xD;
          2. Adults subjects provide written informed consent and adolescent subjects give written&#xD;
             or verbal assent, as appropriate, and parent(s) or legal guardian(s) give written&#xD;
             informed consent&#xD;
&#xD;
          3. Female subjects of childbearing potential must agree to use one of the following forms&#xD;
             of contraception from screening through the last study visit: hormonal (oral, implant,&#xD;
             or injection) begun &gt;30 days prior to screening; barrier (condom, diaphragm, or&#xD;
             cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive&#xD;
             options may also include abstinence, relationship with a same sex partner or partner&#xD;
             who has had a vasectomy at least six (6) months prior to the screening visit&#xD;
&#xD;
          4. Negative urine pregnancy test in all females of childbearing potential (past menarche)&#xD;
&#xD;
          5. Male subjects of sexual activity age: willing to use contraception or abstain from&#xD;
             sexual activity beginning with the first exposure to study drug and continuing until&#xD;
             discharged from the study due to completion or Early Termination&#xD;
&#xD;
          6. Healthy, as determined by the Investigator (in consultation with the Medical Monitor,&#xD;
             as needed), based on medical and dental history, concurrent illnesses, laboratory&#xD;
             results, concomitant medications, oral cavity assessment, and targeted physical&#xD;
             examination (general, extraoral, head and neck) during Screening.&#xD;
&#xD;
             Note: Subjects on a stable dose of medication may be eligible for screening and will&#xD;
             be assessed by the medical monitor on a case-by-case basis.&#xD;
&#xD;
          7. Have a minimum of 12 bicuspids and molars with a minimum of 8 molars and bicuspids NOT&#xD;
             having restorations, crowns or sealants&#xD;
&#xD;
          8. Demonstrated ability to expectorate â‰¥2 mL of stimulated saliva in 5 minutes&#xD;
&#xD;
          9. Have a salivary S. mutans of 1.0 x 10^5 CFUs/mL or greater at Screening using mitis&#xD;
             salivarius-bacitracin (MSB) agar plating&#xD;
&#xD;
         10. Willing to refrain from using non-study dentifrice and other non-study oral care&#xD;
             products (oral care rinses, fluoride products, etc.) during the study&#xD;
&#xD;
         11. Willing to postpone elective dental procedures (e.g., dental cleanings) between&#xD;
             Screening and final post-treatment visit (End of Study or Early Termination)&#xD;
&#xD;
         12. Willing and able to comply with oral hygiene and diet instructions&#xD;
&#xD;
         13. Able to communicate with the Investigator/study center personnel, understand and&#xD;
             comply with the study requirements, and willing to return for protocol-specified&#xD;
             visits at the appointed times&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Advanced periodontal disease&#xD;
&#xD;
          2. Active caries lesion(s) within 30 days prior to study drug administration (confirmed&#xD;
             by comprehensive caries examination including standard radiographs). Subjects&#xD;
             presenting with insipient, non-cavitated lesion(s) are not excluded.&#xD;
&#xD;
             Note: If radiographs are deemed appropriate for the study and taken within 6 months&#xD;
             prior to the Screening visit, these may be used for determining eligibility and are&#xD;
             not required to be repeated at Screening&#xD;
&#xD;
          3. Partially erupted teeth where the entire crown is not erupted or an operculum is&#xD;
             present&#xD;
&#xD;
          4. Medical condition (e.g., artificial heart valve, history of infective endocarditis,&#xD;
             cardiac transplant with valvular dysfunction, congenital heart disease or total joint&#xD;
             replacement) for which antibiotics are recommended prior to dental visits and/or&#xD;
             procedures&#xD;
&#xD;
          5. Pathologic lesions of the oral cavity (suspicious or confirmed)&#xD;
&#xD;
          6. Full dentures or permanent orthodontic appliances, e.g., braces, buccal or lingual&#xD;
             brackets. Note: Partial dentures, removable retainers and night guards are not&#xD;
             excluded, provided that they are cleaned regularly throughout the duration of the&#xD;
             study&#xD;
&#xD;
          7. Use of systemic antibiotics, topical oral antibiotics, any immunosuppressant therapy,&#xD;
             and steroids, beginning 30 days prior to Screening until the end of study&#xD;
             participation&#xD;
&#xD;
          8. Medical history indicating the woman is pregnant, breastfeeding/lactating or has a&#xD;
             positive urine pregnancy test&#xD;
&#xD;
          9. Participation in a clinical trial or receipt of a non-FDA approved therapy within 30&#xD;
             days prior to study drug administration (depending on the specifics, participation in&#xD;
             an observational study is not necessarily excluded)&#xD;
&#xD;
         10. Participation in a previous C16G2 clinical trial having received either C16G2 Strip,&#xD;
             C16G2 Varnish or Placebo Varnish&#xD;
&#xD;
         11. Presence of any condition or concurrent illness, which in the opinion of the&#xD;
             Investigator, would compromise normal immune function (e.g., diabetes, rheumatoid&#xD;
             arthritis, lupus, liver disease, organ transplant, etc.), interfere with the use of&#xD;
             study dentifrice and oral care products, or interfere with the ability to comply with&#xD;
             study requirements, or jeopardize the safety of the subject or the validity of the&#xD;
             study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pittaway, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Plaza West II Dental Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John F. Pittaway, DMD</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <disposition_first_submitted>July 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 31, 2018</disposition_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

